Private pharmacy RSV and dengue fever vaccine services launch in UK 'first'

Private respiratory syncytial virus (RSV) and dengue fever vaccination services are now available in community pharmacies in a “first” for the sector, a clinical services provider has announced.  

Pharmadoctor launched both new private vaccination services on Thursday

The UK’s “first” private RSV vaccination service package was this week (October 12) launched by Pharmadoctor, C+D can reveal.

The vaccination service is now available to over 12,000 pharmacists partnered with the clinical service provider, Pharmadoctor said in a statement released yesterday (October 14).

Common but highly contagious respiratory virus RSV can be indistinguishable from a cold in healthy adults and older children but can lead to severe respiratory illness like bronchiolitis and pneumonia in infants, young children, the elderly and those with compromised immune systems, it added.

Read more: JCVI recommends RSV vaccination programme for babies and over-75s

Pharmadoctor’s new RSV vaccination service package will “initially” use GSK’s RSV vaccine Arexvy, which was launched in the UK earlier this year, it said.

However, Pharmadoctor added that it plans to include “more RSV vaccine options…as they become available in the UK”.

Patients aged 60 and older are eligible to receive the private vaccine and Pharmadoctor expects pharmacists to be able to charge between £180 and £200 per vaccination, it said.

The Pharmadoctor RSV vaccination service package costs pharmacists £299 per year, or £79 for those with a Pharmadoctor “unlimited package”, it added.

“Pivotal step”

Pharmadoctor’s medical director Dr Colin Davidson said that "making the RSV vaccine available across the UK” is “a pivotal step in addressing the burden of respiratory illnesses” by “not only [protecting] individuals” but also “reducing the broader healthcare strain”.

In June, the Joint Committee on Vaccination and Immunisation (JCVI) recommended an immunisation programme to protect infants and older adults against RSV.

Read more: ‘No plans' to reinstate free flu jabs for 50-64-year-olds despite uptake drive

The JCVI highlighted that the NHS only offers an RSV immunisation programme to “a very small group of infants known to be at very high risk of severe complications”.

But JCVI chair Professor Sir Andrew Pollard said that the JCVI recommended an expanded RSV vaccination programme, saying that the committee recognised “that there is a significant burden of RSV illness in the UK population, which has a considerable impact on the NHS during winter”.

Dengue fever jabs

Meanwhile, Pharmadoctor also told C+D that it is “proudly” offering its partner pharmacies the opportunity to be “the first in the country” to offer their patients vaccination against dengue fever – also as of Thursday.

Pharmadoctor chief executive Graham Thoms said that the provider expects pharmacists will charge between £80 and £90 per dengue vaccination, taking from that a profit margin of around 40%. 

The clinical services provider added that it will be adding manufacturer Takeda’s recently UK licensed dengue vaccine Qdenga to its travel clinic service, which costs pharmacists £699 per year.

Read more: Why you should set up a travel clinic in your community pharmacy

The addition is free for pharmacies that have already purchased the travel clinic service, it said.

Patients aged four years old and above will be eligible for the jab, Mr Thoms added. 

Dengue – commonly known as dengue fever - is a mosquito-borne viral infection that is more common in tropical and subtropical climates, Pharmadoctor said.

The incidence of dengue has “grown dramatically” around the world in recent decades, with global cases reported to the World Health Organisation (WHO) increasing from just over 500,000 cases in the year 2000 to 5.2 million in 2019, according to the WHO.

Sign in or register for free

Kate Bowie

Read more by Kate Bowie

Kate Bowie joined C+D as a digital reporter in August 2023 after graduating from a master’s in journalism at City, University of London. She began covering the primary care beat at the end of 2022, when she carried out several health investigations focused on staffing issues, NHS funding and health inequalities.

Latest from News

Revealed: 2024/25 contract cash uplift already paid

 
• By 
 • comment

Following this week’s announcement of the long-awaited pharmacy funding deal, C+D has learned that contractors have already received the additional £106 million in retrospective funding for 2024/25.

Antidepressants added to NMS from October

 
• By 
 • comment

The government has announced an expansion to and fresh payment structure for the new medicine service (NMS) to “boost mental health support in the community”.

‘Smaller than usual’ PQS reinstated under new funding deal

 
• By 
 • comment

The government has announced that the pharmacy quality scheme (PQS) will be “reinstated” in 2025/26 as part of the new funding deal but is “smaller than usual”.

More from Clinical